PPT-End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced

Richard S Finn MD Professor of Clinical Medicine Division of Hematology Oncology Director Signal Transduction and Therapeutics Program Jonsson Comprehensive Cancer

survival sorafenib 2019 progression sorafenib survival progression 2019 hcc 2018 pfs treatment placebo disease median study kudo phase advanced

Presentation Embed Code

<iframe width="560" height="315" src="https://www.docslides.com/embed/809087" frameborder="0" allowfullscreen></iframe>

Download Presentation

Download Presentation The PPT/PDF document "End-Points and Rationale for Phase III T..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.